Cart
sales@molnova.com
PDL-1 cpd 10
CAS No. 2767424-13-3
PDL-1 cpd 10( —— )
Catalog No. M37623 CAS No. 2767424-13-3
PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 76 | Get Quote |
|
| 5MG | 113 | Get Quote |
|
| 10MG | 187 | Get Quote |
|
| 25MG | 380 | Get Quote |
|
| 50MG | 545 | Get Quote |
|
| 100MG | 745 | Get Quote |
|
| 200MG | 981 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePDL-1 cpd 10
-
NoteResearch use only, not for human use.
-
Brief DescriptionPDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.
-
DescriptionPD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2767424-13-3
-
Formula Weight377.44
-
Molecular FormulaC21H23N5O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (331.18 mM; Ultrasonic (<60°C)
-
SMILESCC1=C(C=CC=C1COC=2N=C(NCCNC(C)=O)N=CN2)C3=CC=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Russomanno P, et al. Interfering with the Tumor-Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors. J Med Chem. 2021;64(21):16020-16045. ?
molnova catalog
related products
-
PD-1-IN-1
PD-1-IN-1 is a small molecule inhibitor of programmed cell dealth-1 (PD-1).
-
BMS-1166-N-piperidin...
BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride, a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor, inhibits the PD-1/PD-L1 interaction with an IC50 of 39.2 nM.
-
Tislelizumab
Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.
